Cargando…

PReS-FINAL-2143: Treat-to-target strategy in juvenile idiopathic arthritis: experience in 175 newly-diagnosed patients

Detalles Bibliográficos
Autores principales:	Negro, G, Consolaro, A, Verazza, S, Bracciolini, G, Rosina, S, Pignataro, R, Civino, A, Martini, A, Ravelli, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043642/ http://dx.doi.org/10.1186/1546-0096-11-S2-P155

Ejemplares similares

PReS-FINAL-2132: Defining criteria for high disease activity in juvenile idiopathic arthritis: definition and validation of juvenile arthritis disease activity score cutoffs
por: Consolaro, A, et al.
Publicado: (2013)

PReS-FINAL-2098: Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 313 patients
por: Verazza, S, et al.
Publicado: (2013)

PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report
por: Varnier, GC, et al.
Publicado: (2013)

PReS-FINAL-2011: Preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis
por: Marafon, D, et al.
Publicado: (2013)

PReS-FINAL-2345: Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis
por: Giancane, G, et al.
Publicado: (2013)

PReS-FINAL-2193: Assessment of construct validity of new measures of global disease activity, physical function and quality of life in children with juvenile dermatomyositis
por: Ferrari, C, et al.
Publicado: (2013)

PReS-FINAL-2164: Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis
por: Pignataro, R, et al.
Publicado: (2013)

PReS-FINAL-2028: ANA positivity and a younger age at onset, but not disease category, predict the risk of uveitis in italian children with juvenile idiopathic arthritis
por: Schiappapietra, B, et al.
Publicado: (2013)

PReS-FINAL-2176: Declines in levels of disease activity and physical disability in children with juvenile idiopathic arthritis seen in standard clinical care over the last 25 years
por: Consolaro, A, et al.
Publicado: (2013)

Agreement between objective and subjective definitions of inactive disease, remission and minimal disease activity in juvenile idiopathic arthritis
por: Schiappapietra, B, et al.
Publicado: (2011)

IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis
por: Giancane, Gabriella, et al.
Publicado: (2016)

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis
por: Bracciolini, GP, et al.
Publicado: (2014)

Do parent's global rating of well-being and disease activity of children with juvenile idiopathic arthritis yield different information?
por: Ullmann, N, et al.
Publicado: (2008)

Comparison of physician's, parent's and patient's global ratings made on linear or 21-circle visual analogue scales (VAS) in juvenile idiopathic arthritis (JIA)
por: Dalprà, S, et al.
Publicado: (2008)

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis
por: Consolaro, A, et al.
Publicado: (2011)

PReS-FINAL-2010: Predictive value of whole-body MRI in juvenile dermatomyositis
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013)

Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?
por: Allegra, Maddalena, et al.
Publicado: (2014)

PReS-FINAL-2167: What is the potential of intra-articular corticosteroid injections to induce sustained remission in children with juvenile idiopathic arthritis?
por: Lanni, S, et al.
Publicado: (2013)

A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
por: Bava, Cecilia, et al.
Publicado: (2019)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis
por: Frid, P, et al.
Publicado: (2013)

PReS13-SPK-1332: Assessment of disease activity and damage in juvenile idiopathic arthritis
por: Ravelli, A
Publicado: (2013)

PReS-FINAL-2018: The P53 gene polymorphisms and juvenile idiopathic arthritis
por: Kozhevnikov, A, et al.
Publicado: (2013)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
por: Consolaro, A, et al.
Publicado: (2008)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

PReS-FINAL-2097: Evaluation of gait in children with juvenile idiopathic arthritis
por: Baydogan, SN, et al.
Publicado: (2013)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Children with juvenile idiopathic arthritis currently followed in a tertiary care setting have a better psychosocial well-being than healthy peers
por: Bertamino, M, et al.
Publicado: (2011)

PReS-FINAL-2150: Antiocular antibodies in children with juvenile idiopathic arthritis-associated uveitis
por: Walscheid, K, et al.
Publicado: (2013)

PReS-FINAL-2081: Accelerometer-assessed daily activity in juvenile idiopathic arthritis
por: Noergaard, M, et al.
Publicado: (2013)

PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
por: Reinards, TH, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

PReS-FINAL-2007: Adolescent clinic for young patients with juvenile idiopathic arthritis
por: Sørensen, SK
Publicado: (2013)

PReS-FINAL-2060: The role of stress factors in the onset of juvenile idiopathic arthritis
por: Stepanenko, N, et al.
Publicado: (2013)

PReS-FINAL-2099: Assessing the standards of oral health in children and adolescents with juvenile idiopathic arthritis
por: Trehane, SJ, et al.
Publicado: (2013)

Development and initial validation of a new functional ability tool for juvenile dermatomyositis
por: Varnier, GC, et al.
Publicado: (2011)

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o3ceu45v1bjgo3q79dkloovb0l